Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Artivion Inc (AORT)

Artivion Inc (AORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
AORT
5 Must-Read Analyst Questions From Artivion’s Q4 Earnings Call StockStory - Wed Feb 18, 11:32PM CST

5 Must-Read Analyst Questions From Artivion’s Q4 Earnings Call

AORT : 38.00 (+1.28%)
AORT
Artivion (AORT) Stock Trades Down, Here Is Why StockStory - Fri Feb 13, 10:30AM CST

Artivion (AORT) Stock Trades Down, Here Is Why

AORT : 38.00 (+1.28%)
AORT
AORT Q4 Deep Dive: Stent Graft and On-X Growth Offset By Tissue Flatness, Guidance Highlights Pipeline StockStory - Thu Feb 12, 11:32PM CST

AORT Q4 Deep Dive: Stent Graft and On-X Growth Offset By Tissue Flatness, Guidance Highlights Pipeline

AORT : 38.00 (+1.28%)
AORT
Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations StockStory - Thu Feb 12, 3:58PM CST

Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations

AORT : 38.00 (+1.28%)
Artivion: Q4 Earnings Snapshot AP - Thu Feb 12, 3:45PM CST

Artivion: Q4 Earnings Snapshot

AORT : 38.00 (+1.28%)
Artivion Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire - Thu Feb 12, 3:05PM CST

Fourth Quarter Highlights:

AORT : 38.00 (+1.28%)
AORT
What To Expect From Artivion’s (AORT) Q4 Earnings StockStory - Tue Feb 10, 9:08PM CST

What To Expect From Artivion’s (AORT) Q4 Earnings

AORT : 38.00 (+1.28%)
Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting PR Newswire - Mon Feb 2, 7:00AM CST

1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity

AORT : 38.00 (+1.28%)
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results PR Newswire - Thu Jan 29, 3:05PM CST

ATLANTA , Jan. 29, 2026 /PRNewswire/ --  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter 2025 financial...

AORT : 38.00 (+1.28%)
MIR
2 Stocks Under $50 to Research Further and 1 We Avoid StockStory - Mon Jan 26, 10:34PM CST

2 Stocks Under $50 to Research Further and 1 We Avoid

AMSC : 33.78 (-2.88%)
MIR : 21.47 (+0.09%)
AORT : 38.00 (+1.28%)

Barchart Exclusives

Nvidia Dumped Recursion Pharmaceuticals Stock. Should You? Barchart - 1 hour ago
Nvidia sold its position in Recursion Pharmaceuticals, while others keep a measured outlook. Does this divergence signal risk or opportunity? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot